Technology | July 18, 2014

FDA Approves Freedom Portable Driver Powering SynCardia Total Artificial Heart

Syncardiac, driver, artificial heart

July 18, 2014 — The Freedom portable driver has received U.S. Food and Drug Administration (FDA) approval for use with the SynCardia temporary total artificial heart as a bridge to transplantation in cardiac transplant candidates who are clinically stable.

“With the FDA approval letter for the Freedom portable driver, SynCardia certified centers may now use the Freedom portable driver with all of their clinically stable patients,” said Michael Garippa, SynCardia CEO and president. “These patients can be discharged and live in their homes and communities while they wait for their matching donor hearts. We anticipate that this will save patients, hospitals and insurance companies thousands of dollars through eliminating most in-hospital costs for this portion of patient care.”

The FDA premarket approval study (PMA) of the Freedom driver excluded patients needing IV therapy or outpatient dialysis, Garippa explained. With the FDA approval of the Freedom PMA study, stable patients who need IV therapy and/or outpatient dialysis will now be able to be discharged from the hospital with the Freedom driver and take care of those conditions as needed as a walk-in patient.

The PMA involved 22 SynCardia certified centers in the United States that provided the Freedom driver to 96 SynCardia total artificial heart patients. An additional 10 patients were given the Freedom under compassionate-use exemptions at nine other centers.

Those 106 patients received 58 total years of support starting when they were first switched to the Freedom portable driver in the U.S. study. The SynCardia total artificial heart with the Freedom drive system allowed 75 percent of those patients to be discharged from the hospital, while 86 percent of the 106 patients either were bridged to heart transplants or were alive and supported by the system as of June 30, 2014.

“Most Freedom patients are free to exercise, eat out at restaurants, sleep in their own beds and socialize, all of which help contribute to better outcomes for these patients’ human heart transplants,” Garippa said.

The 13.5-pound Freedom driver can be carried in a backpack, shoulder bag, walker or a rolling caddy. It powers the total artificial heart with precisely calibrated pulses of air and a small amount of vacuum so that the diaphragm is in the proper position to accept the next filling of blood into each artificial ventricle.

Like a heart transplant, the SynCardia total artificial heart is designed to eliminate the source of end-stage biventricular failure by replacing both failing ventricles and the four heart valves of a patient.

The Freedom runs on lithium-ion batteries that are re-charged using a standard electrical outlet or a car charger that can be used in autos and many boats.

The Freedom was approved in Europe in March 2010 and in Canada in May 2011.

For more information: www.syncardia.com

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Overlay Init